Our Investments

We are full life cycle investors supporting scientists and entrepreneurs at any stage where we identify opportunity, from academic programs in need of industry sponsorship all the way to mature publicly traded companies.

Select Investments

Armo BioSciences is an immuno-oncology company with a pipeline of novel interleukins for cancer.
Athira is a clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function.
Attune is developing small molecules for hereditary angioedema.
AveXis is a Dallas-based company developing gene therapy for spinal muscular atrophy, an often progressive and disabling muscle wasting disease.
Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™).
Beta Bionics is the developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.
Biomea Fusion is a precision medicine company with the mission to revolutionize drug development to create more effective therapies for cancer patients.
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.
Dermtech has developed a non-invasive adhesive patch for the diagnosis of metastatic melanoma.
Encoded is developing life-changing therapeutics for severe genetic disorders that are not addressable with existing gene therapy approaches.
Establishment Labs is developing safer next-generation cosmetic implants.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells to restore hair cells lost in noise-induced hearing loss.
Immunocore is a London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.
Immunovant is developing a FCRN antibody with broad potential in antibody-mediated autoimmune disease.
iTeos Therapeutics is designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs).
Backed by RTW Investments, Ji Xing is a privately held, leading Shanghai-based biotechnology company committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
LaJolla Pharmaceutical is a California biotech focused on endogenous peptides and therapies for rare diseases.
Landos Biopharma is developing first-in-class oral therapeutics for autoimmune diseases including inflammatory bowel disease (IBD).
Milestone is a late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).
NiKang is a preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.
Nuance is a China-based privately held fully integrated pharmaceutical company engaged in creating value through China’s specialty pharmaceutical markets, with an established focus on iron deficiency, pain management and respiratory conditions
Odonate Therapeutics is developing a novel oral taxane for breast cancer.
Orchard Therapeutics is a biotechnology company dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases.
Orchestra Biomed is the developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.
Principia is a late-stage biopharmaceutical company bringing therapies to patients with high unmet medical needs in immune-mediated diseases.
Prometheus Biosciences is discovering and developing novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD).
Pulmonx is a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema.
ReGenX is the most broadly licensed AAV capsid technology platform in gene therapy. ReGenX’s own pipeline is focused on metabolic, CNS, and retinal diseases.
Rocket Pharma brings hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.
RXi was a RNAi company that developed innovative therapeutics that address significant unmet medical needs.
Solid Biosciences is dedicated to developing therapies for Duchenne Muscular Dystrophy, a disease characterized by progressive muscular weakness in boys.
Stoke is developing antisense oligos that target RNA splicing to increase gene expression for the treatment of severe genetic diseases, including Dravet Syndrome.
Tarsus is focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis
Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™).
Athira is a clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function.
Beta Bionics is the developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.
Biomea Fusion is a precision medicine company with the mission to revolutionize drug development to create more effective therapies for cancer patients.
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.
Encoded is developing life-changing therapeutics for severe genetic disorders that are not addressable with existing gene therapy approaches.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells to restore hair cells lost in noise-induced hearing loss.
Immunocore is a London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.
iTeos Therapeutics is designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs).
Backed by RTW Investments, Ji Xing is a privately held, leading Shanghai-based biotechnology company committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
Landos Biopharma is developing first-in-class oral therapeutics for autoimmune diseases including inflammatory bowel disease (IBD).
Milestone is a late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).
NiKang is a preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.
Nuance is a China-based privately held fully integrated pharmaceutical company engaged in creating value through China’s specialty pharmaceutical markets, with an established focus on iron deficiency, pain management and respiratory conditions
Orchestra Biomed is the developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.
Prometheus Biosciences is discovering and developing novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD).
Pulmonx is a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema.
Rocket Pharma brings hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.
Tarsus is focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis

The investments listed above do not include names of investments for which RTW is under non-disclosure obligations. Others are not included for the protection of RTW’s competitive edge.

  • Let's Talk.

    Contact us to learn more about RTW’s expertise, insight and experience in identifying and working with companies focused in areas of breakthrough innovation.
  • This field is for validation purposes and should be left unchanged.
RTW-logos-white

RTW INVESTMENTS, LP
40 10th Avenue, Floor 7
New York, NY 10014

Phone: (646) 597-6980
Fax: (646) 597-6998

COMPANIES
companies@rtwfunds.com

HR INQUIRIES
hr@rtwfunds.com

INTERNSHIP OPPORTUNITIES
intern@rtwfunds.com

Copyright © RTW Investments, LP. All rights reserved.

Access our Annual Results 2019 Presentation Recording

  • This field is for validation purposes and should be left unchanged.